Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
NCT01307267 · View on ClinicalTrials.gov ↗
Study Summary
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
Conditions Studied
Interventions
- DRUG rituximab
- DRUG PF-05082566
Study Locations (20)
California
- City of Hope — Duarte
- UC San Diego Moores Cancer Center-Investigational Drug Services — La Jolla
- UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital) — La Jolla
- UC San Diego Moores Cancer Center — La Jolla
- Research Administration Office: Clinical Research Unit — Los Angeles
- Ronald Reagan UCLA Medical Center, Drug Information Center — Los Angeles
- UCLA Bowyer Clinic — Los Angeles
- UCLA Hematology-Oncology Clinic — Los Angeles
- Stanford University Medical Center — Palo Alto
- Stanford University Medical Center — Palo Alto
- UC San Diego Medical Center - Hillcrest — San Diego
- Santa Monica UCLA Hematology & Oncology Clinic — Santa Monica
- Stanford University Medical Center — Stanford
Georgia
- Emory University Hospital Midtown — Atlanta
- Emory University Hospital — Atlanta
- The Emory Clinic, Building A — Atlanta
- The Emory Clinic — Atlanta
- Winship Cancer Institute — Atlanta
District of Columbia
- Georgetown University Medical Center Department of Pharmacy, Research — Washington D.C.
- MedStar Georgetown University Hospital — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2011-06-21 |
| Est. Completion | 2019-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01307267
The ClinicalTrials.gov registry entry for NCT01307267 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Carcinoma, Non-Small-Cell Lung appearing as the primary indexed condition, and to 2 interventions — of which rituximab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01307267 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Georgia, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01307267 about?
NCT01307267 is a clinical study titled "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab". A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
What is the current status of trial NCT01307267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2011-06-21. Estimated completion is 2019-02-20.
What conditions does trial NCT01307267 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Carcinoma, Renal Cell, Malignant Melanoma, Lymphoma, Large B-Cell, Diffuse. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01307267?
The interventions under investigation include: rituximab (DRUG), PF-05082566 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01307267?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01307267 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.